"There was an unusually high placebo response rate in this trial," noted Robert L. Roe, M.D., Corcept's President and head of development.
"At Day 56, for example, approximately 80 percent of the patients in both of the arms of the study were responders as measured by a 50 percent improvement in BPRS PSS score."
While corcept big wigs are disappointed of these results, the two other Phase 3 trials are underway whose results they expect to announce by the end of this year or early next year.
CORLUX® is Corcept’s lead product for the treatment of the psychotic features of Psychotic Major Depression (PMD). A potent GR-II antagonist, CORLUX® is administered orally to patients once per day for seven days and appears to reduce the effects of the elevated and abnormal release patterns of cortisol seen in PMD.
Read the full press release.
Comment Preview